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Abstract: Acute myocardial infarction (AMI) is the leading cause of death
among cardiovascular diseases. Among the numerous attempts to develop
coronary marker concepts into clinical strategies, cardiac troponin is known as
a specific marker for coronary events. The cardiac troponin concentration
level in blood has been shown to rise rapidly for 4–10 days after onset of AMI,
making it an attractive approach for a long diagnosis window for detection.
The extremely low clinical sensing range of cardiac troponin levels
consequently makes the methods of detection highly sensitive. In this review,
by taking into consideration optical methods applied for cardiac troponin
detection, we discuss the most commonly used methods of optical
immunosensing and provide an overview of the various diagnostic cardiac
troponin immunosensors that have been employed for determination of
cardiac troponin over the last several years.

Biosensors are designed to detect target molecules in medical
diagnostic procedures.1,2,3 In principle, they are generally fabricated by
immobilizing the biological elements of, for instance, antibody, DNA or
RNA, and enzyme on the surface of a transducer to convert the
interaction between biological elements and target molecules into
quantifiable signals.4,5,6,7,8 Due to the high affinity of antibodies to their
target molecules, antibody and antigen binding are supposed to be
practical methods for detecting specified biomarkers in human
samples.9 Cardiovascular biosensors are classified as an extremely
important and crucial diagnosing system not only for patient survival
but also for reduction in cost and a great deal of time in successful
prognosis of the disease. Acute myocardial infarction (AMI)1 has
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remained a leading cause of morbidity and mortality worldwide.10
Among many biomarkers, the earliest biomarkers for the detection of
myocardial ischemia included aspartate aminotransferase, total lactate
dehydrogenase, and lactate dehydrogenase isoenzymes.11 Another
cardiac biomarker, creatine kinase (CK), is a cytosolic carrier protein
for high-energy phosphates.12
Creatine kinase MB (CK-MB) is an isoenzyme of creatine kinase
that is most abundant in the heart. CK-MB is present in a small
fraction of other organs such as the small bowel, uterus, prostate, and
diaphragm.13 Therefore, the specificity of CK-MB can be reduced.
Specificity comparison between CK-MB and other cardiac biomarkers,
including troponin, showed that troponin (I or T) has been determined
to have nearly absolute myocardial tissue specificity for myocardial
damage and has high clinical sensitivity for myocardial ischemia.14,15
Troponin is known as a complex of three regulatory proteins—troponin
C, troponin I, and troponin T—that are related to skeletal and cardiac
muscle contractions. Troponin complex form can perform as a receptor
of calcium ions to induce structural changes through actin and myosin
providing contraction.16,17 The troponin complex has three subunits:
troponin C, which binds calcium; troponin I, which inhibits actin–
myosin interactions; and troponin T, which attaches the troponin
complex by binding to tropomyosin and facilitates contraction.
Troponin C is expressed by cells in both cardiac and skeletal muscle. In
contrast, the amino acid sequences of troponins I and T are unique to
cardiac muscle.18
Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are
biomarkers for AMI diagnosis. Cardiac troponins (cTns) have been
recommended for predicting and treating cardiovascular disease,
especially AMI, because of their high sensitivity and specificity. cTnI is
known as a specific marker for coronary events.19 Cardiac troponins as
regulatory proteins control the calcium-mediated interaction of actin
and myosin, which results in contraction and relaxation of striated
muscle. Serum troponin levels in patients who are free of heart
disease are very low or undetectable. After AMI symptoms, the level of
troponin increases in 24 h and could increase up to 14 days after acute
myocardial infarction.20 Following the myocardial damage, the troponin
complex is broken up and the individual protein components are
released into the bloodstream. Detection of cTnI and cTnT in
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peripheral blood indicates cardiomyocyte damage. Because AMI is the
most important cause of cell damage, both intracellular located cTns
have become an integral part in the diagnosis of AMI. For this
indication, determinations of cTn concentration and release kinetics
are superior to all other biomarkers. Therefore, cTnI and cTnT are the
preferred markers for the diagnosis of AMI. However, cTn indicates
and provides an estimate of cardiomyocyte damage irrespective of its
cause. Therefore, differential diagnoses of elevated cTns are to be
considered. Electrocardiography (ECG) and cTn form the diagnostic
cornerstones and complement clinical assessment for patients with
acute chest pain, angina pectoris, or other symptoms suggestive of
acute myocardial infarction. The troponin I clinical sensing ranges are
extremely low, and the methods for detection are required to be highly
sensitive.21,22,23,24 Therefore, the diagnostic sensitivity of troponin
compared with other tests would be extremely high.
Electrocardiography and cardiac troponin form the diagnostic
cornerstones and complement clinical assessment for patients with
acute chest pain, angina pectoris, or other symptoms suggestive of
acute myocardial infarction.
In this review, we summarize major advances and
developments of optical biosensor technologies for detection of cardiac
troponin I in biological fluids. To achieve the increasing demand of
quick troponin diagnosis and consequently the clinical therapeutics, a
plethora of methods have been used for detection of the troponin
family, including enzyme-linked immunosorbent assay (ELISA),25
chemiluminescent immunoassay,26 fluoroimmunoassay,27 electrical
detection,28 surface plasmon resonance (SPR) detection,29 and
colorimetric protein array.30 These optical biosensors for cardiac
troponin detection, in comparison with electrochemical biosensors for
troponin detection, are more bulky and expensive and also require
difficult labeling procedures. For instance, colorimetric, fluorescence,
and luminometric types of sensors involve difficult labeling procedures
based on indirect indicator signal schemes. The significant merits of
optical biosensors are high sensitivity and rapid antigen detection.
It is worthwhile to consider the challenges in cardiac troponin
detection biosensors such as improving sensitivity and specificity, low
cost, low power, ease of miniaturization, and point-of-care
capability.31,32
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Optical biosensors
In optical biosensors, the transducing structure is the critical
part and different transducers can be used for generating an optical
change, including grating couplers,33 resonant mirror,34,35 surface
plasmon resonance (SPR),36 interferometry,37 reflectrometric
interference spectroscopy,38 ellipsometry,39 and total internal reflection
fluorescence (TIRF).40
The SPR technique is based on measuring the refractive index of
very thin layers of material adsorbed on a metal. In SPR
immunosensing, the antibodies have been immobilized on the surface
of a thin metal film, such as gold, deposited on the reflecting surface
of a glass prism. When interactions between the antigens and
immobilized antibodies occur, a change in the refractive index as
variation in light intensity reflecting from the back of the film will be
detected.41,42,43
Localized surface plasmon resonance (LSPR) is a powerful
technique for chemical and biological detection. LSPR is generated by
light when it interacts with conductive nanoparticles (NPs) that are
smaller than the incident wavelength. In LSPR, by incidence of light to
the NPs, the electric field is deposited to collectively excite electrons of
a conduction band, and the result is coherent localized plasmon
oscillations with a resonant frequency and is affected by the
composition, size, geometry, dielectric environment, and separation
distance of NPs.44
The generation of a guided mode in the SPR planar substrate
improves the performance of SPR sensors. Plasmon waveguide
resonance is based on the deposition of a dielectric layer over a gold
or silver film. For this purpose, many conductive or dielectric materials
have been used, including silica and titanium dioxides. Guided modes
are highly sensitive to changes in the refractive index with both
polarizations.45,46 Fig. 1 shows a schematic of the plasmon waveguide
resonance biosensor.45
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Fig.1. Schematic showing the plasmon waveguide resonance biosensor.45

Various integrated optical SPR sensors using slab waveguides,
channel waveguides, and even more waveguide structures have been
developed. Fig. 2 shows a schematic SPR method in an optical
biosensor.47

Fig.2. Schematic showing the SPR method in optical biosensor.47
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Optical biosensors are based on the alteration in the phase,
polarization, or frequency of the input light that is related to
biorecognition processes. Optical biosensors are classified into different
categories such as colorimetric, fluorescence, luminescence and
surface plasmon resonance.32 In biosensors based on colorimetric or
fluorescence detection, the target or biological elements are labeled
with fluorescent tags or dyes.32 The presence of target molecules is
determined when the change in intensity of fluorescence or color
signal occurs. Colorimetric measurement is directly visible and
convenient, whereas the sensitivity is much lower. In general,
biosensors based on these methods have shown effective
performance, but the demerits are sensitivity, miniaturization, and
cost efficiency. SPR can be used to detect interaction between
biological elements that are immobilized on the metal surface and its
biospecific target.48 SPR immunosensors have been proposed for
sensitive and quick detection of human troponin. Recently, biosensors
based on luminescence methods have been developed for cardiac
biomarker detection49,50 and have been categorized into two types,
namely chemiluminescence and electroluminescence.
The limit of detection is known as the lowest concentration of
troponin that can be reliably differentiated. In addition, assays that
have a lower limit of detection are considered more sensitive but not
necessarily more precise. The limit of quantification is the lowest
concentration that can be reliably detected and can produce an
acceptable precision, and consequently the limit of quantification may
be equivalent to the limit of detection or can be at a much higher
concentration.51 The limit of quantification for troponin assay is the
concentration with a total imprecision (coefficient of variation, CV) of
10%. The importance of cardiac-specific troponin is that even small
amounts of cardiac-specific troponin play a critical role in reflecting
incremental risk and indicating myocardial injury.52

Fluorescence-based biosensors for cardiac
troponin detection
Several immunoassay techniques may be used to monitor cTnI.
Fluorescence-based biosensors have been developed to detect
troponin I as well. For troponin I detection, fluoro-microbead guiding
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chip (FMGC) performing by an optical immunoassay has been
reported.53
In 2011, Song and coworkers developed an optical
immunoassay for cTnI. Antibody-tagged fluoro-microbeads were used
to perform a sandwich immunoassay. The target antigen cTnI was
added to cTnI capture antibody immobilized on the DTSP (3,3′dithiobis-propionic acid N-hydroxysuccinimide ester)-functionalized
surface and then antigen antibody bound. Biotin-conjugated cTnI
detection antibody was loaded into the chip and reacted for 30 min.
Immobilized cTnI bound to fluoro-microbead-conjugated antibody. The
microchannel was washed with phosphate-buffered saline (PBS), and
then avidin-conjugated fluoro-microbeads were injected. The bound
fluoro-microbead conjugates were measured directly using a
conventional fluorescence microscope. Fig. 3 shows the design and
schematic diagram of the sandwich assay on fluoro-microbeads
guiding chip.53

Fig.3. (A) Design of the fluoro-microbead guiding chip (FMGC). (B) Photograph of the
FMGC. (C) Schematic diagram of the sandwich immunoassay using antigen–antibody
binding (system 1) and avidin–biotin affinity binding (system 2) on the FMGC. The
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avidin–biotin couple was used to enhance the signal.53 DTSP, 3,3′-dithiobis-propionic
acid N-hydroxysuccinimide ester; SAM, self-assembled monolayer.

Luminescence and colorimetric methods for cardiac
troponin detection
Because of the need for fast diagnosis for clinical therapeutics,
biosensors have been designed to have small size and weight, fast
response time, high sensitivity, and (importantly) ease of operation
and fabrication.54,55 For colorimetry assay, materials such as silicon
chips,56 glass surfaces,57 and gold electrodes58 have been developed.
In 2010, Wu and coworkers proposed a biosensor based on the
colorimetric method for cardiac troponin I detection. They showed that
poly(dimethyl siloxane) (PDMS)–gold nanoparticles (AuNPs) composite
film as a basis with silver enhancement can be employed by the
colorimetric method for detection of cTnI.59 PDMS has merits such as
excellent transparency, outstanding elasticity, good thermal and
oxidative stability, ease of fabrication, and the ability to be sealed with
various materials. Gold nanoparticles can be functionalized as an idle
substrate with antigen, enzyme, and other biomolecules. Hence,
applying AuNPs patterned on PDMS films has a great advantage in
biosensor applications. AuNPs aggregate in a liquid system; therefore,
AuNPs are first immobilized onto PDMS film and then covered with
antibodies. After blocking the surface with bovine serum albumin
(BSA) and capturing cTnI, silver enhancement solution is dropped onto
the surface of the sensor and live photos are taken. AuNPs play the
role of catalyst during reactions of silver reduction, and when protein
covers the surface of NPs, the catalytic property of AuNPs could be
wasted. Differences in the type, quality, and quantity of proteins that
cover the surface of AuNPs influence the amount of reduction in silver
metal and cause the color differences of the reaction mixture. The
detection of cTnI using PDMS–AuNPs composite film is practically used
for clinical diagnosis. The experimental procedure and a schematic
diagram of silver enhancement colorimetric detection of cardiac
troponin I are shown in Fig. 4.59
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Fig.4. Experimental procedure for silver enhancement colorimetric detection of cardiac
troponin I: (A) PDMS chip with HAuCl4 solution; (B) photo of PDMS–AuNPs composite
film; (C) schematic diagram for colorimetric detection.59

Chemiluminescence (CL) and electrochemiluminescence (ECL)
biosensing platforms have been assessed for cardiac marker
detection.60,61 A novel nanoparticle based on an ECL immunosensor
has been employed for sensitive detection of human cTnI.22,62 The
production of luminescence during electrochemical reaction is
considered electrochemiluminescence. A high-sensitivity, wide-linear,
low-background, and simple instrument that can be used for detecting
the acute myocardial infarction biomarkers are taken into account as
the positive characteristics of ECL. The unique property of
nanoparticles in coupling with biomolecules is an important issue for
developing biological nanoprobes.63 AuNPs have been functionalized by
protein via electrostatic and other physical adsorption mechanisms,
and due to the high surface-to-volume ratio of AuNPs, biomolecules
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can be immobilized to the surface of them. Gold nanoparticles were
functionalized by using N-(aminobutyl)-N-(ethylisoluminol) (ABEI)–
AuNPs and are used as labels via the simple seed growth method for
ultrasensitive detection of cTnI in clinical diagnosis.62 Two kinds of
nanoparticles, SA–AuNPs (streptavidin-coated gold nanoparticles) and
ABEI–AuNPs–Ab2 nanoprobes, were used for the ECL immunosensor.
SA–AuNPs enhance the conductivity or electron transfer between
biomolecules and electrode and also improve immobilized capacity.
There are two advantages to applying AuNPs in ABEI–AuNPs–Ab2
nanoprobes. First, AuNPs carry antibodies for recognition of
biomarkers. Second, numerous ECL signal-generating molecules of
ABEI were immobilized on the surface of them for signal amplification.
The biotinylated Ab1 immobilized on the surface of SA–AuNPs/1,3propanedithiol/Au, antigen cTnI, and ABEI–AuNPs–Ab2 nanoprobes
fabricate a sandwich-type ECL immunosensor. The design and
fabrication process are shown in Fig. 5.

Fig.5. Schematic illustration of the fabrication process of the sandwich-type ECL
immunosensor using SA–AuNPs as immobilization matrix and ABEI–AuNPs–Ab2 as
probes.62

According to Fig. 5, when the ABEI–AuNPs–Ab2 probes were
reacted with Ag/BSA/bio-Ab1/SA–AuNPs/1,3-propanedithiol/Au
substrate, strong ECL signals were obtained, and this is attributed to
the ABEI–AuNPs–Ab2 molecules attached on the electrode surface and
is the result of the reaction of ABEI radicals electro-oxidized by ABEI
with hydrogen peroxide (H2O2) besides the catalysis of AuNPs.
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In 2013, Li and coworkers indicated the possibility of a sensitive
label-free ECL immunosensor employed by using luminolfunctionalized gold nanoparticles (luminol–AuNPs) as antibody carriers
for detection of the cTnI acute biomarker.22 Luminol–AuNPs conjugated
biotinylated antibodies against cTnI (biotin–anti-cTnI–luminol–AuNPs)
were assembled onto a streptavidin-coated AuNPs (SA–AuNPs)
modified electrode.
Luminol molecules functionalized the surface of electrode for
generating ECL signals, and they carried numerous biotin–anti-cTnI for
connecting with the SA–AuNPs modified electrode and recognition of
target cTnI. The fabrication process of the label-free ECL
immunosensor using luminol–AuNPs is shown in Fig. 6.

Fig.6. Schematic illustration of the fabrication processes of the label-free ECL
immunosensor using luminol–AuNPs as antibody carriers and sensing platform.22

The ECL reaction of luminol with H2O2 formed electrotransfer
interactions. In the presence of AuNPs as the catalyst and the absence
of cTnI, luminal anions and HO2− in alkaline solution were electrooxidized to L − and O2 − radicals. In the presence of cTnI, biotin–anticTnI–luminol–AuNPs assembled Au electrode captured the target cTnI
and an immune reaction happened. The ECL intensity is dependent on
the concentration of cTnI.22

SPR-based biosensor for cardiac troponin detection
SPR immunosensing includes a thin metal film deposited on the
surface of glass prism, and biorecognition elements containing
proteins/antibodies/DNA/RNA have been immobilized on the surface of
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the sensor.64 When antigen reacts with the biorecognition element, the
refractive index as a variation in light intensity changes.65
The surface plasmon resonance technique has been used for
analytical application in immunosensors.66 The high sensitivity to the
variation of mass on the transducer surface in this technique results
from the refractive index alteration by immobilizing antibodies in
immunosensors.48
In 2007, Dutra and coworkers developed covalently immobilized
antibody against cTnT on gold surface via a self-assembled monolayer
(SAM) of thiols by using cysteamine coupling chemistry.67
Immobilization methods are one of the most imperative aspects for the
development of immunosensors.
SAMs have shown some advantages such as high stability,
acceptable orientation, and easy preparation, and they became a
method to immobilize biological elements for biosensor development.
Mercapto groups attached rigidly versatile SAM to the gold electrode
surface.67 The amino groups of cysteamine SAM via cross-linking by
glutaraldehyde immobilized antibodies on the surface of the sensor. A
schematic of the SPR immunosensor for cTnT detection is shown in
Fig. 7.

Fig.7. Schematic representation of the principle of SPR immunosensor for cTnT
determinations.67
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In this study with SPR software (version 4.1.2 from Eco
Chemie), the response of the SPR sensor was automatically monitored
and antibodies were immobilized covalently via the use of SAMs, and
they allowed repetitive measurement with cost savings.67
In 2007, Dutra and Kubo proposed an SPR sensor in which
streptavidin was immobilized on a replaceable carboxy methyl dextran
hydrogel, which was used for binding biotinylated anti-troponin T
monoclonal antibodies to detect human cardiac troponin T.68 The SPR
sensor component involved a gold-coated glass disc covered covalently
with carboxymethylated dextran.
The dextran matrix, by the functionality of the surface, elevates
the binding capacity of the surface that streptavidin ligand via amino
groups is coupled to dextran. Biotinylated anti-troponin T monoclonal
antibodies interacted with a streptavidin-coated sensor disc and were
monitored by observing changes in the resonant angle.68 The
interaction between biotinylated monoclonal antibodies for cTnT and
streptavidin is shown in Fig. 8.

Fig.8. Illustration of the immobilization scheme of biotinylated monoclonal antibody
cTnT.68

The nonspecific binding on the surface is one of the major
problems in this method, and it can make changes in the resonant
angle. There are several ways to minimize this problem such as
washing after the antigen recognition by immobilized antibody and
blocking free reactive sites by a selective layer.68
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A linear range of detection was from 0.03 to 6.5 ng/ml. The
system presented was possible to measure the cTnT without dilution of
the human serum with good specificity and reproducibility.68
In 2011, Liu and coworkers investigated immobilized troponin T
antibody via SAM comprising a homogeneous mixture of oligo(ethylene
glycol) (OEG)-terminated alkanethiolated and mercaptohexadecanoic
acid (MHDA) on gold by using SPR. Oligo(ethylene glycol) resists the
adsorption of protein from solution and has been employed for surface
grafting. Because of high hydrophilicity, the hydrogen bond accepter,
and the zero net charge, the SAM of OEG is suitable for making the
antifouling surface. The functional group of the OEG cannot cross-link
with biomolecules, and its antifouling ability is lost.69
For this reason, OEG was combined with MHDA and created a
mixed SAM. The MHDA has carboxyl groups that can be coupled with
amine groups on the antibody through 1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride (EDC)/Nhydroxysulfosuccinimide (sulfo-NHS) using active sites.69
Surface modification of the mixed SAM of OEG with MHDA and
immobilization methods for binding antibody are shown in Fig. 9.

Fig.9. Schematic diagram of surface modification for the mixed SAM of OEG and
MHDA and the immobilization method of antibody binding carboxyl groups of MHDA on
Au.69
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The SPR biosensor detected troponin T within 2 min after
injection in a linear detection range lower than 50 μg ml−1, and the
limit of detection (LOD) of cardiac troponin T was 100 ng ml−1, which
is not yet sufficient for clinical diagnostics.69

Other optical-based biosensors for cardiac troponin
detection
One of the methods for troponin detection is based on an
optomagnetic immunoassay technology. This method can be used in
affinity-based assay for the detection of a broad range of biological
molecules, including proteins, small molecules, and nucleic
acid.70,71,72,73
An optomagnetic biosensor based on nanoparticles that are
magnetically actuated and optically detected in a sample fluid has
been proposed for troponin detection.74,75 There are electromagnets
placed above and below the cartridge that generate magnetic forces,
and supermagnetic particles are controlled and accelerated by them.75
In 2009, Bruls and coworkers coated the magnetic nanoparticles
and the sensor surface with antibody, and magnetic nanoparticles
were mixed into sample fluid in the cartridge.75 Due to the large total
surface area of the dispersed nanoparticles, nanoparticles captured
analyte molecules.76 Then, the electromagnets were applied to move
the nanoparticles and localize them at the binding surface. For
removing free and weakly bound particles from the surface, the
magnetic field from the upper magnet is used. The optomagnetic
system, with electromagnets and detection optics, was placed in the
fluid microchamber.75 The design and assay process steps are shown
in Fig. 10.
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Fig.10. Optomagnetic immuno-biosensor based on actuated magnetic nanoparticles.
(A) Schematic showing the assay process in the reaction microchamber: (1) antibodyconjugated magnetic nanoparticles fill microchamber and capture analyte; (2)
electromagnets generate magnetic field that is applied on magnetic particles to
binding to the surface; (3) magnetic field from upper magnet is used to remove
unbound and weakly bound particles. (B) Fluid microchamber placed in the
optomagnetic system with electromagnets and detection optics. Light reflects from the
sensor surface with an intensity that depends on the concentration of nanoparticles at
the surface of the sensor, with the mechanism of frustrated total internal reflection (fTIR). 2D, two-dimensional. (C) Cartridge composed of two plastic parts connected by
double-sided adhesive tape. The outer dimension of the cartridge is 1 × 4 cm. The
cartridge includes a sample inlet, a channel, a reaction microchamber, and a vent. The
volume of the reaction microchamber is 1 μl, and a total sample volume is 10 μl. (D) fTIR image of magnetic nanoparticles bound to the surface of the sensor through an
immunoassay on 31 capture spots of 125 mm diameter each. (E) Schematic real-time
curve of the measured optical signal for a single capture spot. The assay phases A(1)
to A(3) are marked (see panel A). The signal modulation in phase A(2) is due to
switched actuation of the magnetic nanoparticles.75

For detecting the presence of magnetic nanoparticles on the
binding surface, the optical principle of frustrated total internal
reflection (f-TIR)77 was employed and is shown in Fig. 10B.75
Bruls and coworkers developed a fast and sensitive cTnI test
based on actuated magnetic nanoparticles. For this purpose,
nanoparticles that were incubated with sample fluid were injected into
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the cartridge. The actuation protocol was started, and magnetic force
from the lower magnet was applied to particles. Particles carrying cTnI
were concentrated at the surface, and cTnI was bound between
antibody-coated nanoparticles and antibody-coated surface of the
sensor. Then, the optical signal was changed.75
Fluorescence resonance energy transfer (FRET) is known as a
chemical transduction method that describes energy transfer between
two light-sensitive molecules. Donor and acceptor molecules must be
in close proximity. The absorption spectrum of the acceptor must
overlap the fluorescence emission spectrum of the donor. The FRET
biosensors are categorized into two types: intermolecular (or
bimolecular) and intramolecular (or unimolecular).78
In 2008, Stringer and coworkers employed biosensor-based
FRET by using quantum dots as donors and organic dyes as acceptors
for detection of troponin I.79 To detect the fluorescence, a liquid core
waveguide was used that was able to achieve highly sensitive and
accurate measurement. For this purpose, green quantum dot was used
as the donor with an emission peak wavelength at approximately
544 nm, and Invitrogen Alexa Fluor 546 (AF-546) fluorescent dye was
used as acceptor, with the absorption peak wavelength directly
overlapping with the emission peak wavelength of the donor. The
amine-reactive ester on the surface of the quantum dot was created
by using EDC and sulfo-NHS, and then protein A was labeled with
carboxyl-functionalized quantum dot. Mouse anti-troponin I IgG
monoclonal antibody was labeled with AF-546 fluorescent dye, and
then the biosensor complex was fabricated. Antibodies include two FAB
arms and a single FC stem, with FAB being bound to a single FC stem by
means of a hinge region.80,81 Protein A is simultaneously able to bind
two IgG antibodies via the FC portion of the IgG.82 Quantum dotlabeled protein A and mouse anti-troponin I IgG monoclonal antibodylabeled AF-546 fluorescent dye were incubated for 2 h at room
temperature. After that, protein A binds to anti-troponin antibody and
self-assembled optical biosensor is produced. A schematic of the selfassembled optical biosensor architecture is shown in Fig. 11.79
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Fig.11. Schematic of self-assembled optical biosensor architecture.79

To obtain the emission spectrum with significant peak and large
changes in energy transfer, the acceptor-to-donor ratio was given as
4:1 AF-546 to quantum dot. When antibody captures antigen,
conformational change occurs within the antibody structure. Due to
changing distances between quantum dot as donor and AF-546 as
acceptor, the energy transfer is altered.79
Surface-enhanced Raman scattering (SERS) is a technique that
offers orders of magnitude increases in Raman intensity, overcoming
the traditional drawback of Raman scattering.83 SERS is of interest for
trace material analysis, flow cytometry, and other applications where
the current sensitivity/speed of a Raman measurement is insufficient.
The enhancement occurs at a metal surface that has nanoscale
roughness, and the molecules adsorbed onto that surface can undergo
enhancement.83,84 Typical metals used are gold and silver. Preparation
of the surface can be provided through electrochemical roughening,
metallic coating of a nanostructured substrate, or deposition of
metallic nanoparticles (often in a colloidal form).
One of the more recently developed techniques for
immunoassay and DNA detection is surface-enhanced Raman
scattering.85 This technique is of high interest due to its high sensitivity
and potential for multiplexing.62,86,87 Because Raman peaks are much
narrower than fluorescence bands, SERS has potential for multiplex
detection.88 SERS assay was used recently via SERS nano-tags and
magnetic beads for a sandwich immunoassay.89,90 This method
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includes two antibodies: one attached to the surface of magnetic
beads and the other conjugated with a SERS nano-tag. As a result, the
antigen is sandwiched between two antibodies.91
In 2014, Chon and coworkers developed a SERS-based
competitive immunoassay for detection of cTnI and CK-MB.91 For this
reason, monoclonal antibodies for cTnI and CK-MB were immobilized
onto the surface of magnetic beads, and two different types of SERS
nano-tags were used for conjugated target antigen: cTnI and CK-MB.
Samples including free target antigens and the antigens conjugated
onto the surface, SERS nano-tags were injected into magnetic beads,
and competitive reaction between the monoclonal antibodies on the
magnetic beads and free target antigens and the antigens conjugated
on the surface of SERS nano-tags started. By using a small magnetic
bar, the immunocomplexes were separated and the Raman signals of
the remaining SERS nano-tags in supernatant were examined. In this
study, two type of SERS nano-tags were used. Malachite green
isothiocyanate (MGITC) and X-rhodamine-5(and 6)-isothiocyanate
(XRITC) were used as Raman reporter molecules. Hallow gold
nanospheres (HGNs) have been used for conjugating cTnI and CK-MB
antigens.91

Conclusions and perspectives
The importance of cardiac troponin biomarkers for the
fabrication of immunosensors and their application in acute myocardial
infarction concept are known. Fabrication and modification of
immunosensors by the incorporation of biological molecules via
different methods have been carried out to improve the detection of
specified biomarkers.
Recent advances in the optical immunosensing of cardiac
troponin biomarkers was summarized, and the conception of detection
and development of devices based on optical detection principles was
considered and implies that for fabrication of an ideal diagnosis of
cardiovascular diseases at early stages, it is essential to detect cardiac
troponin biomarkers with a simple and sensitive method at very low
levels of troponin through optical measurement in various methods
such as colorimetric, fluorescence, luminescence, and surface plasmon
resonance. Several disadvantages of optical immunosensors, such as
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bulkiness, high cost, and difficult labeling procedures, were described.
Thus, clinical biosensors based on the colorimetric method using
PDMS–AuNPs composite film with silver enhancement have been
successfully attempted for cTnI detection in less than 20 min and a
limit of detection of 0.01 ng/ml. Furthermore, the advantages of the
colorimetric method have been considered in the ease of fabrication
and operation and low cost, whereas in SPR immunosensors the
detection of cTnI in a linear range from 0.03 to 6.5 ng/ml has been
reported. In addition, the detection limit of the mentioned sensors was
0.01 ng/ml with the merits of good repeatability and specificity and
concurrently compared to the fabrication strategy of the biosensor
based on ECL immunosensors for the detection of cTnI. Moreover, ECL
immunosensors, by using luminal–AuNPs as antibody with a wide
range from 0.1 to 1000 ng/ml and a limit of detection of 0.06 ng/ml,
have shown great application potential in clinical and pharmaceutical
analysis, and the optomagnetic biosensor technology based on
actuated nanoparticles for troponin detection has proposed advantages
such as high-sensitivity, rapid multiplexed assays on a small sample
volume and low-cost disposable cartridge.
Finally, the precision of troponin assay improvement will be
continued and will ameliorate earlier diagnosis of acute myocardial
infarction and better risk stratification on the use of the new highly
sensitive assays. It is worth mentioning that testing for troponin has
not been set at the same level of precision as highly automated
methods and still remains as an area for deeper understanding and
efficacy evaluations, and we reported that the optical biosensors with
highly specific detection of troponin have the ability for more
investigation in clinical applications.
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